VitaDX has developed VisioCyt® Bladder, a clinically validated in vitro diagnostic device that utilizes artificial intelligence and digital imaging to detect bladder cancer from urine samples. This non-invasive solution addresses the challenge of early diagnosis, improving patient outcomes by facilitating timely intervention.
Funding
$1.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for bladder cancer detection often involve invasive procedures, causing discomfort and potential complications for patients. Early and accurate detection of bladder cancer is critical for effective treatment and improved patient outcomes.
Solution
VitaDX offers VisioCyt® Bladder, an in vitro diagnostic device that uses artificial intelligence and digital imaging to detect bladder cancer from urine samples. This non-invasive test analyzes urine samples to identify cancerous cells, providing a less invasive alternative to traditional diagnostic methods. The device employs advanced image processing and machine learning algorithms to identify subtle indicators of cancer, enhancing the accuracy and speed of diagnosis. VisioCyt® Bladder is CE IVDR marked and available for prescription through partnerships with anatomical pathology laboratories. The solution aims to improve patient outcomes by enabling earlier detection and intervention.
Target Audience
The primary target audience includes urologists, oncologists, and pathology labs seeking a non-invasive and accurate method for early bladder cancer detection.
Features
- AI-powered image analysis for automated detection of cancerous cells in urine samples
- Non-invasive diagnostic method, reducing patient discomfort and risk
- Clinically validated with CE IVDR marking for diagnostic accuracy and reliability
- Digital imaging technology for high-resolution analysis of cellular structures
- Machine learning algorithms trained to identify subtle indicators of bladder cancer
- Integration with anatomical pathology laboratories for streamlined diagnostic workflows